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 Abstract 
Supercritical gas foaming using CO2 was used to fabricate 
blank poly DL lactide-co-glycolide (PLGA) micro-porous 
foams. Paclitaxel-loaded PLGA foams were also produced for 
the first time using a modification of the supercritical gas 
foaming technique whereby pacltitaxel-loaded PLGA 
microparticle powders obtained from spray drying was 
foamed. In this study, it was found that using polymer 
powders, more compact foams and smaller pores foams may 
be achieved with lower saturation pressures and time which is 
due to the much higher surface area to volume ratio of the 
microparticle powders. Experiments were carried out with 
varying lactide to glycolide ratio of the copolymer PLGA and 
it was shown that the pore size, in vitro swelling behavior and 
drug release profiles may be altered by changing the 
copolymer composition used. The foams fabricated also have 
good mechanical strength which makes it suitable to be 
applied as an implantation material for the post-surgical 
controlled delivery of chemotherapeutic drugs. The residual 
organic solvent content of the paclitaxel-foams were well 
below the allowable limit set by the US Pharmacopeia as 
shown in the present study. The in vitro release profiles over a 
period of 5 weeks showed close to linear release.  
 
Index Terms - Keywords: Supercritical gas foaming 
technique, Poly DL lactide-co-glycolide (PLGA), Micro-
porous foams, Controlled release, Paclitaxel 
 
I. INTRODUCTION 
  
icro-porous polymer foams have important 
applications in tissue engineering as scaffolds [1-3] drug 
delivery systems [4-5]. PLGA is one of the most popular 
biodegradable polymers used in porous foam fabrication as 
it is biocompatible and FDA approved [1,3-5]. The 
degradation rate of the foam may also be controlled by 
careful selection of the copolymer composition and 
 
 
molecular weight [3]. Conventional methods of micro-
porous foam formation such as solvent-casting, particulate 
leaching technique [3] are usually associated with the use 
of large amounts of organic solvents which may require 
extensive purification steps to remove the residual solvent. 
Using supercritical CO2 as the foaming agent, the use of 
organic solvent may be minimized or even eliminated in 
the production of PLGA foams as illustrated in previous 
studies [5].  
The mechanism of supercritical gas foaming technique is 
as follows [1]: Under high pressure CO2, the glass transitin 
temperature (Tg) of PLGA is depressed and a polymer melt 
may be formed at lower temperatures with large amounts 
of dissolved CO2. Upon rapid depressurization, 
thermodynamic instability takes place and the CO2 
molecules cluster and diffuse to form nuclei in the polymer 
matrix. As CO2 leaves the polymer and pressure is 
lowered, the Tg of polymer increases to above the 
operating temperature and vitrifies to form a solid 
polymeric foam 
The micro-porous foams can potentially be used in the 
post-surgical treatment of cancer cells by controlled release 
of chemotherapeutic agent. After a surgical removal of a 
tumor, not all the tumor cells will be removed. A controlled 
release device may be implanted immediately after the 
surgery to target the leftover cells to prevent proliferation 
of the leftover cells [6].  
Paclitaxel is a promising chemotherapeutic agent against 
a wide spectrum of carcinomas [6-12]. It is a highly 
hydrophobic molecule with very low aqueous solubility. 
However, it was found to be associated with problems of 
extremely slow release when encapsulated in compressed 
discs [12]. 
In the present study, fabrication and characterization of 
blank and paclitaxel-loaded micro-porous foams as 
implantation material for post-surgical chemotherapy 
treatment of gliomas as well as other forms of carcinomas 
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were studied and the operating conditions were optimized 
to achieve foams with good mechanical strength and 
controllable pore sizes.  
 
II. EXPERIMENTAL 
A. Materials 
Polymer Poly DL lactide-co-glycolide (PLGA) for a 
range of copolymer composition was used in this study. 
PLGA 5050 Low IV was purchased from Lakeshore 
Biomaterials (Birmingham, AL). PLGA 5050 (Cat No. 
P2191 MW = 40,000 – 75,000 Da), PLGA 6535 (Cat No. 
2066 MW = 40,000 – 75,000 Da), PLGA 7525 (Cat No. 
P1941 MW = 66,000 – 107,000 Da) and PLGA 8515 
(Cat No. 430,471 MW = 50,000 – 75,000 Da) were 
purchased from Sigma Aldrich (St Louis, MO, USA). 
Phosphate Buffered Saline (PBS, pH = 7.4) was 
purchased from Sigma Aldrich (St Louis, MO, USA). 
Paclitaxel was a generous gift from Bristol Myers 
Squibb. Compressed CO2 (Airliquide Paris, France) was 
purchased from Soxal (Singapore Oxygen Air Liquide 
Pte Ltd). Dichloromethane (DCM) (DS1432, 
HPLC/Spectro Grade) and acetonitrile (ACN) (AS1122, 
HPLC/Spectro Grade) were purchased from Tedia 
(Farfield, OH, USA). Millipore water (Millipore 
Corporation, Billerica, MA) was used throughout the 
study.  
B. Experimental Setup and foam fabrication 
A custom-made mold with height and diameters of 10mm 
was machined from a ½” MNPT plug as shown in Figure 
1. For each experiment, approximately 100 mg of polymer 
was loaded into the mold and sealed with a porous stainless 
steel wire mesh. The mold was then fitted onto the high 
pressure vessel and placed in a circulating water bath 
maintained at 35 oC. Saturation pressures from 8 – 10MPa 
and saturation times of 1 – 4 hrs was used in this study. 
The depressurization step was maintained consistently for 
all the experiments at 1/5 opening of the needle valve of 
the automatic back pressure regulator. 
C. Spray Drying of paclitaxel-loaded microparticles 
Paclitaxel-loaded PLGA powders were fabricated using a 
spray drying technique (Buchi Mini Spray Dryer) using as 
a solvent for paclitaxel and PLGA. For all the spray drying 
experiments, 2w/v% polymer solution, airflow rate of 
800NL/min at 70oC, 100% aspirator ratio and 20% liquid 
feed rate was used.  
D. Characterization and in vitro studies 
Scanning Electron Microscopy (SEM, JEOL JSM-5600 
LV, Japan) was used to study the porous structure and 
surface morphology of the polymeric foams fabricated in 
this study.  
Differential Scanning Calorimetry (DSC, 2920 
modulated, Universal V2.6D TA instruments) was carried 
out to determine the glass transition temperatures  of the 
PLGA foams Approximately 2-10 mg of particles was 
loaded onto standard aluminum pans (40mg) with lids. The 
samples were purged with pure dry nitrogen at a flow rate 
of 20 ml/min. A blank aluminum pan was used as a 
reference in all of the analyses. The analysis was carried 
out using a temperature ramp of 10 oC/min from 20 – 200 
oC for blank PLGA foams and from 20 – 250 oC for 
paclitaxel-loaded PLGA foams. 
 Gas Chromatography with Mass Spectrometer detector 
(GC-MSD) was used to determine the residual DCM 
content of the foams. 
High pressure liquid chromatography (HPLC with UV-
visible detectors, Shimadzu) was used to determine the 
encapsulation efficiencies and in vitro release profile of the 
paclitaxel-loaded particles. Discs of geometry 3mm 
diameter by 1mm height were punched from the paclitaxel-
loaded foams and placed in PBS solution in a shaking 
water bath at 37 oC and 120 rpm. At predetermined time 
intervals, PBS solution was removed for sampling and 
fresh buffer was replaced. An ACN: water (50:50 v/v) 
solution was used as the mobile phase for HPLC analysis. 
FIGURE 1. Experimental Setup for supercritical gas foaming technique 
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III. RESULTS AND DISCUSSION 
A. Micro-porous PLGA foams 
Figure 2 shows the interior pore structure of blank PLGA 
foams with different lactide to glycolide content. A 
saturation pressure of 12MPa and saturation time of 4hrs 
was used to generate the foams. From Figure 2, it was 
observed that as the lactide content in the foams increase, 
the mean pore size decrease and which could be explained 
by the increased crystallinity of the polymer. It was also 
observed that PLGA 5050 yield open cell structures with 
interconnecting pores whereas PLGA 6535, PLGA 7525 
and PLGA 8515 generally produced mostly closed cell 
structures.  
The Tg of the foams were studied and Figure 3a and 3b 
shows the exotherm plot of the 4 different copolymers of 
PLGA before and after foaming respectively. The Tg of 
PLGA generally increases as lactide content increases. 
Comparing the Tg of PLGA before and after foaming, for 
all the 4 different copolymers, the Tg increases after 
foaming. This is due to the rapid solidification of the 
polymer during the depressurization step of the foaming 
process. 
The in vitro swelling behavior of the 4 PLGA 
copolymers in PBS maintained in physiological conditions 
was studied. As shown in Figure 4, PLGA 5050 swelled 
by approximately 15% in the first 3 weeks. As the 
glycolide content in PLGA increase, its hydrophillicity 
increase. Therefore, PLGA 5050 is the most hydrophobic 
polymer which attributed to its most pronounced swelling.  
PLGA 6535 and PLGA 8515 showed little changes in 
volume. PLGA 7525 is observed to shrink and this may be 
due to the higher molecular weight (MW 66,000 – 107,000 
Da) of the polymer as compared to the PLGA 5050, PLGA 
6535 and PLGA 8515 used.  
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FIGURE 2. SEM observation of the interior pore structure 
of various blank PLGA foams obtained from polymer 
pellet (as obtained from Sigma Aldrich) using a saturation 
pressure of 12MPa and saturation time of 4hrs 
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FIGURE 3a. Glass transition temperatures of PLGA 5050, 
PLGA 6535, PLGA 7525 and PLGA 8515 before foaming 
FIGURE 3b. Glass transition temperatures of PLGA 5050, 
PLGA 6535, PLGA 7525 and PLGA 8515 after foaming 
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FIGURE 4. In vitro swelling behavior of PLGA foams 
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FIGURE 5. . 2-Step Fabrication process for paclitaxel-loaded 
PLGA foams using combined spray-drying and supercritical 
gas foaming technique 
 
B. Paclitaxel-loaded PLGA foams 
Paclitaxel-loaded PLGA foams were fabricated using a 
two-step process of spray drying followed by supercritical 
gas foaming of the microparticles as illustrated in figure 5. 
The purpose of the spray drying step was to achieve a 
molecular dispersion of paclitaxel in PLGA in the final 
foam product. The drug-loaded formulations studied were 
summarized in table 1 and the 5% drug loaded 
microparticle powders achieved from spray drying and the 
interior pore structures of 5% drug loaded foams are 
illustrated in figure 6a and 6b respectively. Figure 6a 
shows the spray dried powders with diameters ranging 
from 1 – 10 μm. From figure 6b, PLGA 5050 yield open 
cell structures and PLGA 8515 yield closed cell structures 
which are consistent with the results obtained for blank 
PLGA foams. 
The encapsulation efficiencies of the paclitaxel-loaded 
microparticles and foams were studied using HPLC and 
The encapsulation efficiency of paclitaxel from the spray 
dried powders to the final foamed product was determined 
as: 
                      -- (1) 
 
From table 2, the drug encapsulation using the 
supercritical gas foaming technique has very high 
efficiency between 90 – 100%. High encapsulation 
efficiency is a very important factor in most 
pharmaceutical processes as the active ingredient is 
normally very rare and expensive.  
 To determine whether paclitaxel encapsulated was 
molecularly dispersed in the polymer matrix within the 
foam [13-14], a thermogram analysis was carried out on 
the 10% paclitaxel-loaded powders and foams as shown in 
figure 6. Crystalline paclitaxel has an endothermic melting 
peak at 223 oC [15] and from figure 7, no paclitaxel 
melting peak was observed for both the powders and 
foams. This showed that no crystalline paclitaxel was 
present in both formulations and the drug was molecularly 
dispersed in the PLGA polymer matrix.  
 Figure 8 shows the release profile of paclitaxel from the 
5% formulations. The release from 5% drug-loaded PLGA 
5050 (Low IV) has the fastest release rate which can be 
explained by its high affinity for water. Using a more 
hydrophobic polymer PLGA 8515, a much slower release 
rate was achieved. This showed that by selection of the 
copolymer used, the in vitro release of drug from the foams 
may be altered.  
 
 As DCM was used as a solvent during the spray drying 
step, it is important to ensure that the residual DCM 
content in the foams was low enough within the limits of 
500ppm as stated by the US Pharmacopeia.  From Figure 9 
it was shown that the spray dried microparticles has a high 
residual DCM content of approximately 300ppm. After 
freeze drying, the DCM content reduced by approximately 
100ppm. Foaming with supercritical CO2 removed 
approximately 150 ppm of residual DCM from the 
powders which shows the supercritical CO2 removes DCM 
more effectively in much shorter times as compared to 
freeze drying.  
 
TABLE  1. Composition of paclitaxel-loaded foams fabricated 
Sample Polymer Drug loading (%) 
A*-5% PLGA 5050 (Low IV) 5 
D-5% PLGA 8515 (Sigma) 5 
A-10% PLGA 5050 (Sigma) 10 
 
TABLE 2. Encapsulation efficiencies of paclitaxel loaded powders 
and foams 
 
IV. CONCLUSION 
Paclitaxel-loaded PLGA foams were fabricated for 
controlled delivery applications. These foams provide an 
alternative to conventional methods of making implants 
Sample A*-5% A-10% D-5% 
Drug loading in powders 
(mg/mg) 
0.0478 0.1072 0.0490 
Drug loading in foam 
(mg/mg) 
0.0442 0.1072 0.0487 
Encapsulation efficiency (%) 92.6 ~100 99.4 
( ) ( )( )% 100%
mgdrug loading in foam mgEncapsulation efficiency
mgdrug loading in powders mg
= ×
 
 
 
using compression discs. Micro-porous foams have higher  
surface-to-volume ratios, allowing more efficient drug 
release. The release profiles for the micro-porous foams 
fabricated as 3mm discs showed continuous and relatively 
linear release profile up to 5 weeks in vitro. The foams are 
mechanically strong enough to be used as an implant in 
surgical experiments. In addition, by altering the co-
polymer ratio of the PLGA used, the release rate of 
paclitaxel may be modified to address therapeutic 
requirements.  
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